First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure

BERLIN & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002 (also known as NAN-101) for the treatment of congestive heart failure (CHF). GenePHIT is an adaptive, double-blind, placebo-controlled, randomized, multicen